Both PEARL-1 and PEARL-2 studies met their primary efficacy endpoint of superiority of ligelizumab in terms of CFB-UAS7 at week 12 versus placebo (p<0·0001), but not versus omalizumab
prespecified primary comparisons produced concordant estimates in two independently conducted trials
ligelizumab is a well-tolerated anti-IgE treatment, as effective as omalizumab
superiority testing did not formally establish equivalence or non-inferiority against omalizumab
No new safety signals were identified for ligelizumab or omalizumab
systematic adverse-event ascertainment included serious events, predefined special-interest events, and adjudication
Ligelizumab treatment resulted in a significantly higher cumulative number of angioedema-free weeks at week 12 compared with placebo
prespecified regression analysis supports the placebo comparison, with singleton retention limiting strength
Derived from the full evaluation — not a separate score.
Strengths
Two independently conducted, identically designed trials produced concordant findings: ligelizumab was superior to placebo but not to omalizumab. This resolves the principal comparative-efficacy question raised by phase 2b results.
↳ Methods, pp.148–149; Results, p.154; Table 2
Interactive Response Technology, stratification, maintained masking, assigned-treatment efficacy analysis, repeated-measures modelling, and multiple imputation support the primary comparisons. Baseline characteristics were balanced across treatment groups.
↳ Methods, pp.149–153; Table 1
The study reports adverse events, serious events, discontinuations, predefined events of special interest, adjudicated anaphylaxis, and a death. Table 3 and the Results provide treatment-group comparisons rather than only aggregate reassurance.
↳ Methods, p.150; Results, pp.155–157; Table 3
Limitations
The final statement that ligelizumab was “as effective as omalizumab” converts failure to demonstrate superiority into an affirmative equality claim. The trials were not designed as formal equivalence or non-inferiority studies.
↳ Discussion, p.157; Table 2
Non-White participants were relatively underrepresented, and adolescent efficacy findings were exploratory and based on small samples. These constraints limit confidence in subgroup transferability despite broad geographic recruitment.
↳ Results, pp.154–155; Discussion, p.157
The funder participated in design, data collection, analysis, interpretation, and report writing, and sponsor employees conducted the statistical and safety analyses. These roles are fully disclosed but limit analytic independence.
↳ Role of the funding source, p.153; Contributors and Declaration of interests, p.158
The primary conclusion is supported by concordant estimates from two large, masked, active-controlled and placebo-controlled phase 3 trials, with the hierarchical sequence terminating as prespecified after superiority to omalizumab was not shown. Randomisation, assigned-treatment efficacy analysis, missing-data handling, and safety ascertainment are described in detail across the Methods, Figure 2, and Tables 1–3. Reporting is reduced by the Discussion’s description of ligelizumab as “as effective as omalizumab,” because the design tested superiority rather than equivalence or non-inferiority. The broad international programme has direct clinical and regulatory relevance, but limited subgroup representation and the absence of an advantage over omalizumab constrain transferability and uptake.
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
Strong4.1
Confidence highThe two phase 3 trials resolve the clinically important question of whether ligelizumab outperforms omalizumab while independently confirming efficacy against placebo. The negative active-comparator result is informative but limits the magnitude of the therapeutic advance.
“Both doses of ligelizumab were superior to placebo (p<0·0001), but not to omalizumab, in both studies.”
Central allocation, maintained masking, assigned-treatment efficacy analysis, multiple imputation, hierarchical testing, and systematic harms ascertainment support a high methodological score. Two independently conducted replicate trials reached concordant primary conclusions.
“Patients were randomly allocated using the Interactive Response Technology.”
The primary placebo and omalizumab findings are presented consistently in the Summary, Results, and Table 2. The final statement that ligelizumab was “as effective as omalizumab” is stronger than a failed superiority comparison formally establishes.
“ligelizumab is a well-tolerated anti-IgE treatment, as effective as omalizumab”
The paper connects its findings to treatment guidelines, prior omalizumab trials, and phase 2b ligelizumab evidence while acknowledging representativeness, adolescent, missing-data, and dose-selection limits. Some mitigation language, particularly regional stratification in response to racial representativeness, does not fully resolve the stated external-validity concern.
“Generalisability of the studies might be restricted by the relatively low prevalence of non-White patients”
Lower confidence on Positioning — domain match limited.
Caveats4 of 4 checks
Allocation totals, efficacy and safety denominators, effect estimates, and the primary conclusion are consistent across the Summary, Figure 2, and Tables 1–3. Protocol amendments and the hierarchical testing sequence are also described consistently.
Ethics, consent, prospective registration, conflicts of interest, and a controlled data-sharing pathway are declared. The funder participated directly in all major stages from design through analysis, interpretation, and report writing, which warrants disclosure-aware interpretation but does not establish unreliability.
Flags: 4 declared / 5 total
31 of 31 checkable references verified
31 references in manuscript 1 reference confirmed by manual review
References not verified automatically are resolved manually within 24 hours.
No retraction or expression of concern found in Crossref (includes Retraction Watch).
Sources: Crossref (incl. Retraction Watch) ✓
Where this paper’s evidence sits on the path from initial observation to real-world use.
Two completed phase 3 trials across 347 sites provide evidence close to regulatory and clinical decision use. Readiness as a differentiated treatment is constrained because ligelizumab did not show superiority to the licensed comparator.
“but not to omalizumab, in both studies”
AI-generated, human-governed. Something look off? Contact us to request a review.
Keep reading
Other papers Nabu has evaluated blind, starting with the same field.
Ana Maria Giménez-Arnau, Robert Szalewski, Michihiro Hide, et al. · 2025 · Basic medicine
At week 52, patients randomized to remibrutinib showed sustained improvements in change from baseline in weekly Urticaria Activity Score
SupportedMaria Mironova, Bachir A. Taouli, Richard L. Ehman, et al. · 2026 · Clinical medicine
MRI proton density fat fraction (MRI-PDFF) is the most accurate noninvasive measure of steatosis (thresholds of 6.4%, 17.4% and 22.1% for grades ≥1, ≥2 and 3), and a ≥30% relative reduction is associated with histologic response.
SupportedRiedl, Farkas, Aygören-Pürsün, et al. · 2024 · Clinical medicine
Oral sebetralstat provided faster times to the beginning of symptom relief, reduction in attack severity, and complete attack resolution than placebo.
Well-supported